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Background/Aims
The influence of external factors such as opioids and alcohol has been extensively investigated for various segments of the 
gastrointestinal tract. However, the association between their use and the development of esophagogastric junction outflow 
obstruction disorders (EGJOODs) is unknown. Therefore, the aim of this study is to analyze prevalence and clinical relevance of opioids 
and alcohol intake in patients with EGJOODs.
Methods
In this single-center, retrospective study, we reviewed clinical and pharmacological data of 375 consecutive patients who had 
undergone high resolution impedance manometry for EGJOODs. EGJOODs were classified according to the Chicago classification 
version 3.0 and to recently published normal values for test meals. Demographics, manometric data, and symptoms were compared 
between different groups using Pearson’s chi-squared test, Fisher’s exact test, and multivariate analysis. A P < 0.05 was considered 
significant.
Results
EGJOOD was found in 30.7% (115/375) of all analyzed patients. The prevalence of opioids (14.8% vs 4.2%, P = 0.026) was 
significantly higher in patients with EGJOODs compared to patients without EGJOODs. Additionally, excessive alcohol consumption 
(12.2% vs 3.5%, P = 0.011) was associated with EGJOODs. Excessive alcohol consumption was especially frequent in the non-
achalasia esophagogastric junction outflow obstruction subgroup (16.2%) and opioid use in the achalasia type III subgroup (20.0%).
Conclusions
We found a significant association between EGJOODs and opioid as well as excessive alcohol consumption. This underlines the 
importance of detailed history taking regarding medication and ethanol consumption in patients with dysphagia. Further prospective 
studies on mechanisms undelaying esophagogastric junction dysfunction due to opioids or alcohol are warranted.
(J Neurogastroenterol Motil 2019;25:205-211)
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Introduction  
Esophagogastric junction outflow obstruction disorders (EG-
JOODs) are a group of esophageal motility disorders often char-
acterized by an impairment of food intake and symptoms such as 
dysphagia, odynophagia, regurgitations, and weight loss. Hence, 
affected individuals often suffer a significantly reduced quality of 
life.1 EGJOODs are characterized by an elevated integrated relax-
ation pressure (IRP) during high-resolution impedance manometry 
(HRIM) and are further subdivided into achalasia type I-III and 
esophagogastric junction outflow obstruction (EGJOO) accord-
ing to Chicago classification (CC; version 3.0). This categorization 
depends on the level of impairment of peristalsis and the esophageal 
pressurization pattern upon swallowing (Fig. 1).2 Current standard 
testing protocols of esophageal physiology incorporate single low-
volume water swallows that frequently fail to detect a significant 
quantity of esophageal motility disorders and usually do not evoke 
symptoms. Additional testing such as multiple rapid swallows and, 
more recently, meal testing offer a more physiologic insight into 
patient deglutition dynamics and better symptom association (Fig. 
1E and 1F).3 While the diagnostic process and further classifica-
tion into achalasia type I-III and EGJOO is well established, the 
underlying etiology and pathophysiological processes are not fully 
understood. Esophageal peristalsis and lower esophageal sphincter 
(LES) relaxation are processes primarily controlled by ganglionic 
cells of the myenteric plexus, which can either induce esophageal 
smooth muscle cell contraction or relaxation, depending on the neu-
rotransmitter released.4,5 Hence, neurodegenerative, autoimmune 
and viral processes causing an imbalance between the excitatory and 
inhibitory transmission, eg, by the loss of ganglion cells, are thought 
to be involved in the pathogenesis of EGJOODs.6-10 The classical 
EGJOO (CC v3.0), which is characterized by elevated IRP but 
preserved peristalsis, could also be triggered by other factors such 
as hiatal hernia, impaired crural relaxation, or a mechanical obstruc-
tion, potentially caused by fibrotic stricture.11 Furthermore, the 
expression of opioid receptors was shown in the esophageal body 
and LES, suggesting a potential influence of opioids on esophageal 
motility and esophagogastric junction (EGJ) relaxation.12-15 Indeed 
a higher IRP as well as lower distal latency on esophageal pres-
sure topography have been shown.12 Moreover, in patients with 
dysphagia and chronic opioid use an impaired LES relaxation and 
simultaneous esophageal waves were noticed.16 However, a deeper 
knowledge on opioid induced EGJOOD is still scarce.
Not only opioids but also alcohol seems to affect the upper gas-
trointestinal tract. The most known effect of excessive alcohol con-
sumption is the development of esophageal varices as a consequence 
of liver damage. While there is accordance with the increased 
prevalence of gastroesophageal reflux in alcoholics, there are incon-
sistent data of the impact on the LES. Reduced pressure as well as 
A B C
D E F
Figure 1. Clouse plots of high-resolution impedance manometry of the different esophagogastric junction outflow obstruction (EGJOO) disorders 
with achalasia type I (A), type II (B), type III (C), and EGJOO Chicago classification version 3.0 (D). Clouse plot of a single water swallow of a 
patient with an EGJOO in the standardized test meal (E). Clouse plot of the same patient during a rice test meal (F). The y-axis corresponds to 
the distance from proximal to distal esophagus, the x-axis constitutes the time. The local pressure at a given time-point is color coded (low pressure 
= blue, intermediate pressure = green/yellow, and high pressure = red/purple).
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a hypertensive LES have been described in conjunction with alco-
hol.17-19 Moreover, alcohol has recently been linked with esophageal 
dysmotility,20,21 but its role in the development of EGJOODs is still 
unclear. Therefore, the aim of this study is to analyze the prevalence 
and clinical relevance in terms of symptomatic esophageal dysfunc-
tion of opioids and alcohol intake in patients diagnosed with EG-
JOODs.
Materials and Methods  
We reviewed data of 375 consecutive patients for alcohol con-
sumption (sporadic, regular, and excessive) and opioid use who 
had undergone HRIM after being referred to our tertiary refer-
ral center for symptoms of esophageal dysfunction between 2015 
and 2017. All patients underwent endoscopic evaluation including 
esophageal biopsies to rule out structural etiologies prior to HRIM. 
Inclusion criteria were age older than 18 years and signed general 
informed consent. Ethics approval was obtained for the analysis 
(BASEC-Nr. 2017-00930).
High-resolution Impedance Manometry
HRIM was performed in a standardized protocol.22 The cath-
eter was inserted nasally in seated position, following local anesthe-
sia with lidocaine gel of the nostrils. Resting pressures of the lower 
and upper esophageal sphincters were measured after an adaption 
period of approximately 2 minutes. Then, 10 single swallows, each 
with 10 mL of water, were performed in semi-upright position. Af-
terwards, patients were asked to eat a test meal consisting of cooked 
plain white rice (200 g portion) at liberty, but within a maximum 
period of 8 minutes, as previously discussed.3,23 Before and after the 
test meal, a rapid drink challenge of 200 mL water using a drinking 
straw was performed.
Esophagogastric Junction Outflow Obstruction 
Classification
HRIM findings were classified according to CC v3.0 based on 
10 single water swallows. EGJOODs were subdivided in achalasia 
type I-III and EGJOO (Fig. 1).2 Patients not classifying for EG-
JOO according to CC v3.0 were reevaluated for EGJOO accord-
ing to recently published indicative HRIM values3 during the test 
meal (Fig. 1D-F).
Opioids and Alcohol
Data on alcohol consumption and opioid use were collected 
from medical records. Alcohol consumption (sporadic and/or regu-
lar) was assessed by patient history. Excessive alcohol consumption 
was defined as > 2 standard units (24 g alcohol) daily for men and 
> 1 standard unit (12 g alcohol) for women according the Federal 
Center for Health, Germany. Opioid use was assessed by patients’ 
medication lists. In all opioid users morphine equivalent doses 
(MED) were calculated.
Statistical Methods
Statistical analysis was performed with R version 3.2.0 (R 
Foundation for Statistical Computing, Vienna, Austria). Numerical 
data are presented as mean ± standard deviation (SD) for normally 
distributed data, and as median and interquartile range (IQR) in 
not normally distributed data. Normal distribution was assessed 
visually with normal quantile-quantile plots. For 2-group compari-
son of categorical data, Pearson’s chi-squared test, Fisher’s exact 
test, and odds ratios (OR) were used. The multivariate analysis was 
based on the type of EGJOOD, opioid, and alcohol consumption 
as well as demographics. For the analysis of MED in relation to 
EGJOOD Kruskal Wallis test was used. A P-value < 0.05 was 
considered statistically significant. All tests were 2-tailed.
Results  
Patient Characteristics and Demographics
A total of 375 consecutive patients with no evidence of organic 
disease at upper endoscopy were considered. The prevalence of 
EGJOODs among all analyzed patients was 30.7% (115/375). 
Major motility disorders other than EGJOODs were diagnosed 
in 20.3% (75/375) of patients and minor motility disorders in 6.6% 
(25/375) of cases. In the group of EGJOODs the prevalence of 
achalasia type I was 2.6% (3/115), type II 24.3% (28/115), type III 
8.7% (10/115), EGJOO (CC v3.0) 30.4% (35/115), and EGJOO 
(standardized test meal [STM]) 33.9% (39/115). Demographics 
of the group with EGJOODs were significantly different compared 
to the non-EGJOOD group regarding age (64 years vs 53 years, 
P < 0.001), but not regarding gender (46.9% vs 52.7%, P = 
0.362). Indication for HRIM (multiple symptoms accepted) were 
dysphagia (45.4%), upper abdominal discomfort (40.3%), acid re-
gurgitation (37.1%), heartburn (33.9%), and regurgitation of liquid 
and solid foods (18.4%).
Association of Esophagogastric Junction Outflow 
Obstruction Disorders With Opioids
Indications for opioid consumption were musculoskeletal pain 
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syndromes in 20/28 patients (71.4%), codeine use for cough in 2 
(7.1%), methadone maintenance treatment in 2 (7.1%), loperamide 
use for chronic diarrhea in 1 (3.6%), and unknown indications in 3 
patients (10.7%). All included opioid types are listed in Figure 2.
Opioid consumption was significantly more prevalent in pa-
tients with EGJOODs (14.7% [17/115]) as compared to patients 
without EGJOODs (4.2% [11/260]) (OR, 3.9; 95% CI, 1.8-
8.9) (Fig. 3A). Within the group of opioid consumers, patients 
with EGJOODs consumed significantly higher doses of morphine 
(P = 0.023) (Fig. 4). Prevalence of EGJOODs in patients with 
MEDs higher than 100 mg per day was 100.0% (7/7) while it was 
47.6% (10/21) in patients consuming less than 100 mg.
Patients with achalasia type III had the highest prevalence of 
opioid usage (20.0% [2/10]), followed by EGJOO (water swallow, 
CC v3.0; 17.1%, 6/35), EGJOO (STM 15.4% [6/39]), achalasia 
type II (10.7% [3/28]), and achalasia type I (0.0% [0/3]) (Fig. 
3B). No association of opioid consumption with other major and 
minor motility disorders was found.
Figure 2. Number of patients using opioids.
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Figure 3. Prevalence of opioid and excessive alcohol consumption in patients according to esophagogastric outflow obstruction disorder (EG-
JOOD). (A) Prevalence of opioid consumption and excessive alcohol (EtOH) consumption in patients with EGJOOD versus patients without 
EGJOOD. (B) Prevalence of opioid consumption and excessive EtOH consumption in patients with achalasia type I-III, esophagogastric outflow 
obstruction (EGJOO) Chicago classification version 3.0, EGJOO in test meals and patients without any EGJOOD. *P < 0.01, generalized linear 
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Figure 4. Morphine equivalent doses (MED) in opioid consumers 
in relation to esophagogastric junction outflow obstruction disorder 
(EGJOOD). The Kruskal-Wallis test was used for statistical analysis.
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Association of Esophagogastric Junction Outflow 
Obstruction Disorders With Alcohol Consumption
Of all patients diagnosed with EGJOODs, 12.2% (14/115) 
were found to excessively consume alcohol versus only 3.5% (9/260) 
in the group of patients without an EGJOOD (OR, 3.9; 95% CI, 
1.6-9.5) (Fig. 3). In a subgroup analysis we also found a signifi-
cantly different prevalence of EGJOODs according to the amount 
of alcohol consumption (P = 0.006). In excessive alcohol consumer 
the prevalence of EGJOODs was 60.9% (14/23), in occasional al-
cohol consumers 25.8% (34/132), in patients with rare alcohol con-
sumption 25.0% (15/60) and in abstinent patients 32.5% (52/160).
In the subgroup analysis of EGJOODs (achalasia type I to III 
vs non-achalasia EGJOO, according to CC v3.0 and STM), we 
found excessive alcohol consumption in only 4.8% (2/41) of achala-
sia patients but 16.2% (12/74) of patients with an EGJOO itself (P 
< 0.001).
Effect of Opioids and Excessive Alcohol 
Consumption on Upper Gastrointestinal Symptoms
Dysphagia and regurgitation were found significantly more of-
ten in patients with EGJOODs (OR, 18.5; 95% CI, 10.2-35.7 and 
OR, 23.0; 95% CI, 11.8-48.9, respectively) (Fig. 5A). In contrast, 
other symptoms such as heartburn, upper abdominal discomfort, 
chronic cough, and cervical globus sensation were predominantly 
found in patients without EGJOODs. Interestingly, a subgroup 
analysis showed a trend towards a higher prevalence of dysphagia in 
the group of non EGJOODs patients if those patients were treated 
with opioids (Fig. 5B). No other symptoms were influenced by 
concurrent opioid usage. Excessive alcohol consumption, however, 
did not influence any of the described symptoms.
Discussion  
In this single-center, retrospective study, we reviewed the data 
of 375 consecutive patients with unremarkable endoscopy who had 
undergone HRIM for symptoms of esophageal dysfunction. In 
order to increase the diagnostic sensitivity for EGJOODs, STMs 
were used additionally to the single water swallows as published 
recently.23 In particular, we investigated the association between 
esophageal abnormalities and alcohol as well as opioids use. Opioid 
usage has recently become a global epidemic, most pronounced in 
North America.24-26 Similarly, the rate of excessive alcohol abuse has 
increased significantly in many parts of the world.27-29 Hence, the 
understanding of adverse effects of opioids and alcohol abuse with 
potential effects on esophageal motility is of evermore importance. 
Our analysis revealed several findings: first, we found that the 
prevalence of opioid usage was significantly higher in patients with 
EGJ outflow obstruction compared to the group without an EG-
JOOD. Interestingly we also found in the context that within the 
group of opioid consumers, patients with EGJOODs consumed 
significantly higher doses of opioids suggesting a dose dependent 
opioid effect. It has to be pointed out that all opioids were taken for 
indications unrelated to EGJOODs. Interestingly, patients diag-
nosed with achalasia type III had the highest prevalence of opioid 
consumption, followed by EGJOO. In contrast, we neither found 
an association of major motility disorders such as hypercontractile 
esophagus nor minor motility disorders with opioid usage.
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Second, our analysis revealed that dysphagia, a cardinal symp-
tom of achalasia, tended to be more frequent in patients without 
EGJOOD that were treated with opioids. This indicates that in 
addition to the well-known adverse effects like constipation and 
nausea, opioids might also cause esophageal symptoms even in the 
absence of a quantifiable EGJOODs, suggesting either subclini-
cal outlet dysfunction or an influence on the sensory component. 
In agreement to the above mentioned investigation, a recent study 
analyzing the prevalence of opioid usage in a group of patients di-
agnosed with achalasia found that opioid usage was most common 
in type III achalasia.13 Furthermore, a study comparing patients 
on and off opioid medication revealed that opioid usage within 24 
hours of HRIM was associated with a higher frequency of EG-
JOO as well as type III achalasia.
Third, we identified a significant association between excessive 
alcohol consumption and EGJOODs, especially in patients diag-
nosed with non-achalasia EGJOO. After the exclusion of external 
compression of the EGJ, the underlying etiology and pathophysiol-
ogy of the EGJOO is poorly understood: a recent study identified 
a decreased immune-reactivity of endothelial nitric oxide synthase 
in the esophageal myenteric plexus, additionally to a significantly 
decreased serotonin-induced relaxation of the LES in ethanol-fed 
rats.20 In line with the limited animal data, we speculate that exces-
sive alcohol consumption might lead to EGJOO by interfering with 
the nitric oxide mediated relaxation of the LES. A possible other 
mechanism might be mediated via an increased rate of gastroesoph-
ageal reflux, which in turn leads to inflammation and consecutive 
stiffening of the EGJ. The latter hypothesis would also explain why 
alcohol abuse is only associated with the EGJOO itself, but with no 
other motility disorders of the esophageal body such as achalasia. 
Other alcohol induced causes might be neuropathy or impairment 
of contractile proteins, as previously hypothesized for bowel motility 
disorders.20
We recognize that our study does have certain limitations. The 
retrospective nature of the study is connected to a risk of confound-
ing factors despite the usage of a multivariate modelling to mitigate 
this problem. Even though the study was conducted at a university 
hospital with patients from a wide geographical area, it was a single 
center study in a tertiary center which further limits the generaliz-
ability. Moreover, we do not have any HRIM data after cessation 
of opioid treatment or excessive alcohol consumption which hinders 
us to directly compare patients “on” and “off ” opioids/excessive 
alcohol. Hence, to reveal the exact pathophysiologic mechanisms 
of opioid and ethanol induced EGJOODs, more basic and clinical 
research, including multicenter studies, are needed.
In summary, our data support the hypothesis of heterogeneous 
pathophysiologic processes and etiology of EGJOODs, which 
might not only be triggered by autoimmune disease as proposed 
for achalasia type I and II.4,9,30 In accordance to the presented data, 
we suggest an important role and dose dependent effect of opioids 
and alcohol in the development of EGJOODs. Especially the high 
prevalence of opioid treatment and excessive ethanol consumption 
in patients diagnosed with achalasia type III and EGJOO may be 
the result of ganglionic dysfunction or imbalance of the proposed 
excitatory and inhibitory neurotransmission of the LES region. 
Since some of these proposed effects are potentially reversible, fur-
ther studies are warranted investigating the replacement or stoppage 
of the identified triggers as a feasible treatment option in patients 
with type III achalasia or classical outflow obstruction. In addition, 
our results emphasize the importance of a detailed history taking re-
garding medication and alcohol consumption in patients presenting 
with suspected esophageal dysfunction and dysphagia.
Financial support: None.
Conflicts of interest: None.
Author contributions: Valeria Schindler and Daniel Runggaldi-
er: designed the study, collected and analyzed the data, and statisti-
cal analysis, and wrote the manuscript; Amanda Bianca: collected 
and analyzed the data and edited the manuscript; Anton S Becker: 
analyzed data, statistical analysis and edited the manuscript; Fritz 
Murray: edited the manuscript; Edoardo Savarino: edited and ap-
proved the manuscript; and Daniel Pohl: study concept, designed 
the study and edited and approved the manuscript.
References  
1. Tuason J, Inoue H. Current status of achalasia management: a review on 
diagnosis and treatment. J Gastroenterol 2017;52:401-406.
2. Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago classifica-
tion of esophageal motility disorders, v3.0. Neurogastroenterol Motil 
2015;27:160-174.
3. Hollenstein M, Thwaites P, Bütikofer S, et al. Pharyngeal swallowing 
and oesophageal motility during a solid meal test: a prospective study 
in healthy volunteers and patients with major motility disorders. Lancet 
Gastroenterol Hepatol 2017;2:644-653.
4. Furuzawa-Carballeda J, Torres-Landa S, Valdovinos MÁ, Coss-Adame 
E, Martín Del Campo LA, Torres-Villalobos G. New insights into the 
pathophysiology of achalasia and implications for future treatment. World 
J Gastroenterol 2016;22:7892-7907.
5. Park W, Vaezi MF. Etiology and pathogenesis of achalasia: the current 
211
EGJOODs Are Associated With Opioids and Alcohol
Vol. 25, No. 2   April, 2019 (205-211)
understanding. Am J Gastroenterol 2005;100:1404-1414.
6. Boeckxstaens GE. Achalasia: virus-induced euthanasia of neurons? Am J 
Gastroenterol 2008;103:1610-1612.
7. Clark SB, Rice TW, Tubbs RR, Richter JE, Goldblum JR. The nature 
of the myenteric infiltrate in achalasia: an immunohistochemical analysis. 
Am J Surg Pathol 2000;24:1153-1158.
8. Kornizky Y, Heller I, Isakov A, Shapira I, Topilsky M. Dysphagia with 
multiple autoimmune disease. Clin Rheumatol 2000;19:321-323.
9. Runggaldier D, Fried M, Pohl D. Recurrent episodes of esophageal 
candidiasis without dysphagia post-Guillain-Barré syndrome: an unusual 
presentation of achalasia. BMJ Case Rep 2017 Published Online First:15 
Oct 2017. doi: 10.1136/bcr-2017-221751.
10. Booy JD, Takata J, Tomlinson G, Urbach DR. The prevalence of au-
toimmune disease in patients with esophageal achalasia. Dis Esophagus 
2012;25:209-213.
11. van Hoeij FB, Smout AJ, Bredenoord AJ. Characterization of idiopathic 
esophagogastric junction outflow obstruction. Neurogastroenterol Motil 
2015;27:1310-1316.
12. Ratuapli SK, Crowell MD, DiBaise JK, et al. Opioid-induced esopha-
geal dysfunction (OIED) in patients on chronic opioids. Am J Gastroen-
terol 2015;110:979-984.
13. Ravi K, Murray JA, Geno DM, Katzka DA. Achalasia and chronic 
opiate use: innocent bystanders or associated conditions? Dis Esophagus 
2016;29:15-21.
14. Liu XB, Liu JF. Expression of dopamine receptors in human lower 
esophageal sphincter. J Gastroenterol Hepatol 2012;27:945-950.
15. Rattan S, Goyal RK. Identification and localization of opioid receptors 
in the opossum lower esophageal sphincter. J Pharmacol Exp Ther 
1983;224:391-397.
16. Kraichely RE, Arora AS, Murray JA. Opiate-induced oesophageal dys-
motility. Aliment Pharmacol Ther 2010;31:601-606.
17. Kaufman SE, Kaye MD. Induction of gastro-oesophageal reflux by alco-
hol. Gut 1978;19:336-338.
18. Keshavarzian A, Polepalle C, Iber FL, Durkin M. Esophageal motor 
disorder in alcoholics: result of alcoholism or withdrawal? Alcohol Clin 
Exp Res 1990;14:561-567.
19. Grande L, Monforte R, Ros E, et al. High amplitude contractions in the 
middle third of the oesophagus: a manometric marker of chronic alcohol-
ism? Gut 1996;38:655-662.
20. Yazir Y, Tugay M, Utkan Z, Utkan T. Effects of chronic ethanol con-
sumption on rat upper gastrointestinal system: functional and histologic 
findings. Alcohol 2012;46:649-655.
21. Bujanda L. The effects of alcohol consumption upon the gastrointestinal 
tract. Am J Gastroenterol 2000;95:3374-3382.
22. Gyawali CP, de Bortoli N, Clarke J, et al. Indications and interpretation 
of esophageal function testing. Ann N Y Acad Sci 2018;1434:239-253.
23. Ang D, Misselwitz B, Hollenstein M, et al. Diagnostic yield of high-
resolution manometry with a solid test meal for clinically relevant, symp-
tomatic oesophageal motility disorders: serial diagnostic study. Lancet 
Gastroenterol Hepatol 2017;2:654-661.
24. Berterame S, Erthal J, Thomas J, et al. Use of and barriers to access 
to opioid analgesics: a worldwide, regional, and national study. Lancet 
2016;387:1644-1656.
25. Fox M, Menne D, Stutz B, Fried M, Schwizer W. The effects of tegas-
erod on oesophageal function and bolus transport in healthy volunteers: 
studies using concurrent high-resolution manometry and videofluoros-
copy. Aliment Pharmacol Ther 2006;24:1017-1027.
26. National Institute on Drug Abuse. Opioid overdose crisis [revised Janu-
ary 2019]. Available from URL: https://www.drugabuse.gov/drugs-
abuse/opioids/opioid-overdose-crisis (accessed 3 March 2019).
27. Grant BF, Chou SP, Saha TD, et al. Prevalence of 12-month alcohol 
use, high-risk drinking, and DSM-IV alcohol use disorder in the united 
states, 2001-2002 to 2012-2013: results from the national epidemiologic 
survey on alcohol and related conditions. JAMA Psychiatry 2017;74:911-
923.
28. Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in 
Europe: epidemiology and analysis of risk factors to identify prevention 
policies. J Hepatol 2018;69:718-735.
29. Babor TF. Out of africa: three threads tying the alcohol industry to an 
emerging alcohol epidemic. J Stud Alcohol Drugs 2018;79:157-158.
30. Furuzawa-Carballeda J, Aguilar-León D, Gamboa-Domínguez A, et al. 
Achalasia--an autoimmune inflammatory disease: a cross-sectional study. 
J Immunol Res 2015;2015:729217.
